The valuation, backed by an investment proposal from an international group, recognises the potential of its technologies in biotechnology, molecular diagnostics and precision medicine.
Santiago de Compostela, 26 October 2026. Biotechnology company Maxwerk Health, headquartered in Galicia, has announced that its proprietary biotechnology R&D portfolio has received a valuation of US$7.5 million, supported by a concrete investment proposal from an international group.
According to the company, the valuation is based solely on its internally developed technologies and research programmes in biotechnology, molecular diagnostics and precision medicine. Its commercial diagnostic services business was not included in the assessment.
A boost to bring innovation into clinical diagnostics
For Maxwerk Health, this milestone represents recognition of the scientific and commercial potential of the technologies it is developing, and strengthens its confidence as it continues to advance its R&D programmes towards validation and commercialisation.
The company’s long-term vision is to translate scientific innovation into accessible diagnostic solutions with real clinical impact. Its goal is to establish itself as a leading biotechnology company in molecular diagnostics, precision medicine and new technologies capable of transforming how diseases are detected and monitored.
In its announcement, Maxwerk Health thanked BIOGA, the Xunta de Galicia, the Consorcio Zona Franca de Vigo and AJE Vigo for their support, highlighting their role in building an ecosystem in Galicia where biotechnology companies can grow, innovate and move forward.
Galician biotech talent with international reach
BIOGA congratulates the entire Maxwerk Health team on an achievement that highlights the value of the R&D being carried out in Galicia and its ability to attract the interest of international investors.
